AstraZeneca is acquiring Belgian biotech EsoBiotec for up to $1 billion to enhance its cancer therapy portfolio. EsoBiotec's innovative ENaBL platform enables rapid, cost-effective cell therapy...
The European Medicines Agency (EMA) is close to authorizing UCB's new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be...
AbolerIS Pharma is a biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through an innovative antibody therapy directed against the novel target CD45RC,...